Responses
Regular and young investigator award abstracts
Clinical trials in progress
399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.